curriculum vitae

Dr. med Michael Haberland, geboren 1972 in Chicago/USA


Werdegang

1991 Abitur am Martin-Schongauer-Gymnasium in Breisach am Rhein
1991 - 2000 Medizinstudium an der Universität Freiburg
1996 - 1997 Promotion am Institut für Virologie in Freiburg, summa cum laude
2000 - 2003 AiP/Assistenzarzt in der Abteilung für Unfallchirurgie, Universitätsklinikum Hamburg-Eppendorf
2001 - 2003 Aufbaustudium Molekularbiologie am Zentrum für Molekulare Neurobiologie, Universität Hamburg
2003 - 2004 Assistenzarzt in der Abteilung für Molekulare Pathologie, Universitätsklinikum Tübingen
2004 - 2008 Postdoctoral fellow, Department of Molecular Biology, UTSW Medical School, Dallas, Texas, USA
2008 - 2009 Assistant professor, Department of Molecular Biology, UTSW Medical School, Dallas, Texas, USA
2010 - 2012 Assistenzarzt, Praxis für Allgemeinmedizin, Leonberg
2012 - 2014 Assistenzarzt Innere Medizin, Kreiskliniken Unterallgäu
2014 Facharzt für Allgemeinmedizin, Übernahme Hausarztpraxis in Ottobeuren

 

Stipendien und Auszeichnungen
 
2002 Young Investigator Award der American Society for Bone and Mineral Research
2004 fortüne – Stipendium, Universität Tübingen
2004 Ruth L. Kirschstein National Research Service Award, NIH
2004 - 2010 Forschungsstipendium, Deutsche Forschungsgemeinschaft

 

 

Veröffentlichungen
 
Keller J, Catala-Lehnen P, Huebner AK, Jeschke A, Heckt T, Lueth A, Krause M, Koehne T, Albers J, Schulze J, Schilling S, Haberland M, Denninger H, Neven M, Hermans-Borgmeyer I, Streichert T, Breer S, Barvencik F, Levkau B, Rathkolb B, Wolf E, Calzada-Wack J, Neff F, Gailus-Durner V, Fuchs H, de Angelis MH, Klutmann S, Tsourdi E, Hofbauer LC, Kleuser B, Chun J, Schinke T, Amling M. Calcitonin controls bone formation by inhibiting the release of sphingosine 1-phosphate from osteoclasts. Nat Commun. 2014 Oct 21;5:5215.
 
Sondergaard BC, Catala-Lehnen P, Huebner AK, Bay-Jensen AC, Schinke T, Henriksen K, Schilling S, Haberland M, Nielsen RH, Amling M, Karsdal MA. Mice over-expressing salmon calcitonin have strongly attenuated osteoarthritic histopathological changes after destabilization of the medial meniscus. Osteoarthritis Cartilage. 2012 Feb;20(2):136-43
 
Backs J, Haberland M. Towards the development of isoform specific HDAC inhibitors – lessons learned from mouse models. In: Histone Deacetylase Inhibitors in medicine; Assam El-Osta and Tom C. Karagiannis (Eds.) Transworld Research Network; ISBN 978-81-7895-496-7; pp. 95-112.
 
Haberland M, Carrer M, Mokalled MH, Montgomery RL, Olson EN. Redundant control of adipogenesis by histone deacetylases 1 and 2. J Biol Chem 2010 May 7;285(19):14663-70.
 
Haberland M, Johnson A, Mokalled MH, Montgomery RL, Olson EN. Genetic dissection of histone deacetylase requirement in tumor cells. Proc Natl Acad Sci U S A 2009 May;106(19): 7751-7755.
 
Haberland M, Mokalled MH, Montgomery RL, Olson EN. Epigenetic control of skull morphogenesis by histone deacetylase 8. Genes Dev 2009 Jul;23(14): 1625-1630.
 
Haberland M, Montgomery RL, Olson, E.N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009 Jan;10(1): 32-42.
 
Montgomery RL, Potthoff MJ, Haberland M, Qi X, Matsuzaki S, Humphries KM, Richardson JA, Bassel-Duby R, Olson, E.N. 2008. Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. J Clin Invest 2008 Nov;118(11): 3588-3597.
 
Szalay G, Sauter M, Haberland M, Zuegel U, Steinmeyer A, Kandolf R, Klingel K. Osteopontin: a fibrosis-related marker molecule in cardiac remodeling of enterovirus myocarditis in the susceptible host. Circ Res 2009 Apr;104(7):851-9.
 
Montgomery RL, Davis CA, Potthoff MJ, Haberland M, Fielitz J, Qi X, Hill JA, Richardson JA, Olson EN. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev. 2007 Jul;21(14):1790-802.
 
Haberland M, Arnold MA, McAnally J, Phan D, Kim Y, Olson EN. Regulation of HDAC9 gene expression by MEF2 establishes a negative-feedback loop in the transcriptional circuitry of muscle differentiation. Mol Cell Biol. 2007 Jan;27(2):518-25.
 
Davis CA, Haberland M, Arnold MA, Sutherland LB, McDonald OG, Richardson JA, Childs G, Harris S, Owens GK, Olson EN. PRISM/PRDM6, a transcriptional repressor that promotes the proliferative gene program in smooth muscle cells. Mol Cell Biol. 2006 Apr;26(7):2626-36.
 
 
Schmidt K, Schinke T, Haberland M, Priemel M, Schilling AF, Mueldner C, Rueger JM, Sock E, Wegner M, Amling M. The high mobility group transcription factor Sox8 is a negative regulator of osteoblast differentiation. J Cell Biol. 2005 Mar;168(6):899-910.
 
Schinke T, Liese S, Priemel M, Haberland M, Schilling AF, Catala-Lehnen P, Blicharski D, Rueger JM, Gagel
RF, Emeson RB, Amling M. Decreased bone formation and osteopenia in mice lacking alpha-calcitonin gene-related peptide. J Bone Miner Res. 2004 Dec;19(12):2049-56.
 
Schinke, T., Haberland, M., Jamshidi, A., Nollau, P., Rueger, J. M., and Amling, M. Cloning and functional characterisation of resistin-like molecule gamma. Biochem Biophys Res Commun 314 (2004) 356-362
 
Nguyen, C. K., Gesicki, M., Tibba, J, Beil T.F., Rueger, J. M., Haberland, M., and Amling, M. Fracture repair and the role of antiinflammatory drugs: Deleterious effects of diclofenac but not of dexamthasone. Osteo.Trauma Care 11 (2003) 6-7
 
Gesicki, M., Tibba, J, Nguyen, C. K., Beil T.F., Rueger, J. M., Haberland, M., and Amling, M. Testosterone is a potent accelerator of fracture healing: Early structural reconstruction and improved biomechanical stability. Osteo.Trauma Care 11 (2003) 3-5
 
Petersen, J. P., Adamietz, P., Haberland, M., Ruecker, A. H., Rueger, J. M., and Meenen, N. M. The healing capacity of cartilage ex vivo. Eur.J.Trauma 28, Suppl.1 (2002) 113.
 
Haberland, M., Gesicki, M., Nguyen, C. K., Tibba, J, Beil T.F., Amling, M., and Rueger, J. M. NSAIDs Impair Fracture Healing. J Bone Miner Res 17, Suppl.1 (2002) 165.
 
Haberland, M., Gesicki, M., Nguyen, C. K., Tibba, J, Amling, M., and Rueger, J. M. Antiinflammatory drugs impair fracture healing. Eur.J.Trauma 28, Suppl.1 (2002) 80.
 
Schilling, A.F., Priemel, M., Beil, T.F., Haberland, M., Holzmann, T., Catala-Lehnen, P., Pogoda, P., Blicharski, D., Müldner, C., Löcherbach, C., Rueger, J.M. and Amling, M.: Transgenic and knock out mice in skeletal research. Towards a molecular understanding of the mammalian skeleton. J Musculoskel Neuron Interact 1 (2001) 275-289.
 
Haberland, M., Schilling A.F., Rueger, J.M. and Amling, M.: THINK BONE: The Novel Paradigm of Central Bone Mass Control. Eur.J.Trauma 27 (2001) 218-225
 
Haberland, M., Schilling A.F., Rueger, J.M. and Amling, M.: Brain & Bone: Central regulation of bone mass. A new paradigm in skeleton biology. J Bone Joint Surg Am 83 (2001) 1871-1876
 
Amling, M., Schilling, A.F., Haberland, M. and Rueger, J.M.: Leptin: factor in the central nervous system regulation of bone mass. Development of a new understanding of bone remodeling, skeletal reconstruction, skeletal preservation, and skeletal repair. Orthopäde 30 (2001) 418-424.
 
Amling, M., Priemel, M., Schilling A.F. and Haberland, M.: Mouse-Models For Osteoporosis. J Musculoskel Neuron Interact 2 (2001) 87-92
 
Haberland, M., Meyer-Konig, U. and Hufert, F.T.: Variation within the glycoprotein B gene of human cytomegalovirus is due to homologous recombination. J Gen Virol 80 ( Pt 6) (1999) 1495-1500.
 
Meyer-Konig, U., Haberland, M., von Laer, D., Haller, O. and Hufert, F.T.: Intragenic variability of human cytomegalovirus glycoprotein B in clinical strains. J Infect Dis 177 (1998) 1162-1169.
 
Meyer-Konig, U., Vogelberg, C., Bongarts, A., Kampa, D., Delbruck, R., Wolff-Vorbeck, G., Kirste, G., Haberland, M., Hufert, F.T. and von Laer, D.: Glycoprotein B genotype correlates with cell tropism in vivo of human cytomegalovirus infection. J Med Virol 55 (1998) 75-81.